Haleon PLC closed 6.66% short of its 52-week high of £4.18, which the company reached on March 4th.

I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered ...

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a ...

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

Pfizer reportedly raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon, ending a years-long separation with the company, per Bloomberg and Yahoo ...

Haleon PLC closed 6.08% below its 52-week high of £4.18, which the company achieved on March 4th.

HSBC analyst Jeremy Fialko downgraded Haleon (HLN) to Hold from Buy with a 420 GBp price target See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...